All In MedTech

FDA Clearance Tracker · P200010-S010

Guardant360 CDx

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jan 27, 2023 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jan 27, 2023

Approved

Time to decision

220 days

Received Jun 21, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P200010-S010
Device name
Guardant360 CDx
Applicant location
Redwood City, CA
Received
Jun 21, 2022
Decided
Jan 27, 2023
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P200010

Device type

Device class
Class III

Every decision under product code PQP

FDA's approval statement

As written in FDA's record.

Approval for expanding the indications for use to include the companion diagnostic claim to identify breast cancer patients with ESR1 missense mutations between codons 310-547 for treatment with ORSERDU (elacestrant).

Source documents

Other decisions for Guardant Health, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.